infecti
diseas
account
global
mortal
virus
respons
onethird
past
year
emerg
reemerg
virus
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
coronavirus
avian
influenza
virus
pandem
influenza
viru
zika
viru
enterovirus
pose
signific
global
public
health
rapid
effect
control
epidem
onset
often
possibl
due
long
time
lag
requir
develop
specif
antivir
vaccin
earli
empir
administr
highli
effect
broadspectrum
antivir
would
improv
patient
outcom
facilit
control
epidem
given
soon
exact
pathogen
identifi
current
strategi
develop
broadspectrum
antivir
agent
mainli
focu
two
aspect
viru
encod
target
host
defens
factor
cellular
machineri
exploit
success
exampl
virustarget
strategi
includ
blocker
viral
attach
well
inhibitor
target
viral
enzym
proteas
polymeras
neuraminidas
intern
structur
aspect
type
interferon
ifn
ifninduc
protein
use
trigger
cellular
machineri
host
defens
suppress
viral
replic
nevertheless
challeng
drug
toxic
emerg
resist
viral
progeni
remain
address
fulfil
requir
rapid
massiv
clonal
replic
virus
must
coopt
distinct
program
meet
heighten
metabol
demand
key
compon
reprogram
rapid
upregul
lipid
biosynthet
pathway
substanti
impact
viral
replic
process
lipid
recogn
structur
element
viral
cellular
membran
virus
induc
format
novel
cytoplasm
membran
structur
compart
viral
genom
replic
assembl
occur
perhap
shield
host
innat
immun
respons
involv
lipid
viral
replic
cycl
share
envelop
nonenvelop
virus
well
dna
rna
correl
viru
infect
host
lipid
metabol
implic
human
cytomegaloviru
hcmv
infect
hcmv
markedli
upregul
flux
much
central
carbon
metabol
particularli
flux
tricarboxyl
acid
cycl
efflux
fatti
acid
biosynthesi
pathway
demonstr
essenti
role
lipid
metabol
reprogram
merscov
replic
envelop
rna
viru
highli
diverg
hcmv
thu
modul
cellular
lipid
metabol
interfer
viru
multipl
may
appeal
broadli
applic
approach
antivir
therapi
end
carri
pharmacolog
screen
lipid
librari
retinoid
deriv
agonist
demonstr
potent
broadspectrum
antivir
activ
vitro
vivo
use
tool
compound
modifi
click
chemistri
identifi
host
cell
sterol
regulatori
element
bind
protein
srebp
direct
bind
target
srebp
bhlhzip
transcript
factor
welldefin
role
regul
cellular
lipid
homeostasi
mammal
two
srebp
gene
express
three
srebp
protein
produc
via
altern
transcript
start
site
wherea
gene
encod
canon
signal
preferenti
drive
express
fatti
acid
biosynthesi
gene
wherea
predomin
transactiv
gene
involv
cholesterol
biosynthesi
intracellular
lipid
movement
lipoprotein
mechanist
find
block
interact
protein
nonpalindrom
sterol
regulatori
element
sre
promoterenhanc
region
multipl
lipogen
gene
inhibit
transcript
thu
revers
virusinduc
lipid
hyperbiosynthesi
collect
studi
identifi
srebpmedi
lipid
biosynthesi
broad
relev
human
viral
infect
repres
srebp
undescrib
target
develop
broadspectrum
intervent
strategi
especi
tackl
novel
virus
caus
emerg
infecti
diseas
understand
host
respons
viru
infect
determin
transcriptom
profil
human
bronchial
epitheli
cell
infect
merscov
gene
ontolog
go
enrich
differenti
express
gene
deg
perform
explor
multipl
aspect
interact
includ
cellular
process
environment
inform
process
genet
inform
process
human
diseas
organism
system
metabol
fig
within
major
categori
metabol
combin
go
item
mani
global
overview
map
compris
subitem
carbon
metabol
fatti
acid
metabol
biosynthesi
secondari
metabolit
biosynthesi
amino
notabl
lipid
metabol
toprank
affect
metabol
pathway
highlight
import
lipid
among
metabol
chang
trigger
merscov
infect
addit
kyoto
encyclopedia
gene
genom
kegg
enrich
analysi
show
steroid
biosynthesi
highli
enrich
pathway
indic
markedli
heighten
lipid
demand
merscov
life
cycl
supplementari
figur
explor
merscov
infect
perturb
lipid
metabol
untarget
lipidom
analysi
perform
merscovinfect
cell
lipid
featur
significantli
chang
p
student
ttest
merscovinfect
cell
select
better
demonstr
chang
lipid
profil
trend
merscov
infect
heatmap
construct
accord
identifi
lipid
list
supplementari
data
shown
fig
chang
lipid
featur
includ
glycerophospholipid
fatti
acid
class
indic
merscov
infect
strongli
perturb
lipid
homeostasi
map
landscap
metabolictranscript
alter
context
viru
infect
perform
integr
transcriptom
lipidom
analysi
simultan
map
gene
lipid
metabolit
differ
pathway
shown
fig
integr
network
model
specif
reveal
glycerophospholipid
metabol
pathway
dramat
modul
merscov
infect
collect
demonstr
merscov
infect
trigger
mark
host
lipid
metabol
chang
investig
import
lipid
metabolit
viru
life
cycl
screen
lipid
librari
use
merscov
viru
infect
colorimetr
assay
reflect
cell
viabil
perform
select
compound
inhibit
cytopath
effect
cpe
develop
upon
viru
infect
fig
screen
condit
optim
moi
h
postmerscov
infect
moi
h
infect
chosen
respect
supplementari
figur
c
lipid
metabolit
antiinflammatori
effect
protect
cell
merscov
infect
aryl
hydrocarbon
receptor
agonist
ficz
apoptosi
regulatori
messeng
ceramid
protect
mdck
cell
infect
notabl
synthet
agonist
exhibit
cell
protect
virus
select
investig
fig
interestingli
r
methandamid
agonist
cannabinoid
receptor
function
increas
lipid
accumul
facilit
viru
replic
nontox
concentr
thu
caus
sever
cpe
viru
control
find
indic
modul
host
lipid
metabol
could
significantli
chang
outcom
viru
infect
thu
corrobor
hypothesi
modul
virusinduc
lipid
reprogram
therapeut
intervent
cytotox
similar
differ
cell
line
supplementari
figur
use
merscov
infect
model
character
antivir
activ
cell
cultur
first
multicycl
viru
growth
assay
perform
plot
viru
replic
kinet
without
strikingli
treatment
reduc
viral
titer
cell
supernat
compar
dimethyl
sulfoxid
dmso
control
infecti
plaqueform
unit
pfu
group
remain
baselin
level
whole
timecours
fig
express
merscov
nucleoprotein
np
dramat
decreas
upon
addit
especi
h
postinfect
hpi
moi
fig
flow
cytometri
show
percentag
merscovinfect
cell
treatment
decreas
dmso
hpi
upper
panel
fig
furthermor
immunofluoresc
stain
merscov
np
suggest
nearcomplet
suppress
viru
infect
upon
treatment
lower
panel
fig
also
significantli
reduc
merscov
replic
multipl
cell
type
includ
lung
kidney
vero
immun
cell
human
primari
monocytederiv
macrophag
mdm
fig
well
human
primari
small
airway
epitheli
cell
hsaec
fig
moreov
suppress
virusinduc
proinflammatori
cytokin
activ
cell
mdm
supplementari
figur
overal
show
potent
antimerscov
activ
cell
cultur
signific
inhibit
viru
replic
cell
protect
antiinflammatori
respons
previous
establish
human
intestin
organoid
intestinoid
altern
rout
viru
transmiss
merscov
ideal
tool
pharmacolog
herein
inocul
intestinoid
moi
merscov
evalu
effect
data
demonstr
treatment
significantli
p
oneway
anova
reduc
merscov
replic
intra
extracellularli
fig
g
hpi
pfu
detect
intestinoid
cultur
supernat
repres
nearli
reduct
titer
compar
dmsotreat
control
fig
inhibit
merscov
also
evidenc
markedli
decreas
express
viral
np
intestinoid
compar
dmsotreat
intestinoid
fig
collect
demonstr
robustli
inhibit
merscov
replic
human
intestinoid
screen
lipid
librari
demonstr
broadspectrum
antivir
potenti
fig
next
investig
vitro
antivir
effect
virus
especi
emerg
respiratori
pathogen
includ
rna
sarscov
viru
zika
viru
zikv
dna
human
adenoviru
type
virus
notabl
inhibit
replic
evalu
virus
inhibit
concentr
rang
nanomolar
micromolar
scale
concentrationdepend
manner
fig
select
index
remark
test
virus
particular
merscov
sarscov
influenza
viru
suggest
potenti
safe
usag
clinic
avail
analog
therapeut
set
broad
spectrum
viral
pathogen
supplementari
figur
evalu
vivo
antivir
activ
first
examin
whether
drug
confer
protect
lethal
challeng
merscov
human
transgen
previou
pharmacokinet
studi
reveal
rel
larg
appar
volum
distribut
small
clearanc
mlminkg
pharmacokinet
behavior
linear
within
dose
rang
mgkg
intraperiton
intraperiton
ip
inocul
maxim
amount
solubl
pb
mgkg
day
result
sign
toxic
supplementari
figur
mice
challeng
pfu
merscov
mice
surviv
receiv
day
ip
inject
wherea
dmsotreat
mice
die
surviv
rate
fig
mice
group
exhibit
significantli
less
bodi
weight
loss
p
student
ttest
dmsotreat
group
day
postinfect
fig
lower
lung
tissu
viru
titer
viral
load
p
student
ttest
day
fig
supplementari
figur
day
postchalleng
viral
rna
load
brain
tissu
mice
undetect
lower
dmsotreat
mice
supplementari
figur
histopatholog
examin
show
alveolar
damag
interstiti
inflammatori
infiltr
lung
tissu
mice
substanti
diminish
compar
control
mice
fig
collect
result
demonstr
effect
protect
mice
lethal
merscov
challeng
inhibit
merscov
replic
virusassoci
pneumonia
enceph
vivo
parallel
antivir
effect
highli
pathogen
avian
influenza
viru
evalu
balbc
mice
challeng
pfu
intranas
treatment
result
significantli
higher
surviv
rate
vs
dmsotreat
control
p
logrank
test
fig
mice
show
less
bodi
weight
loss
dmsotreat
group
day
day
postinfect
fig
mean
viral
rna
load
lung
tissu
mice
significantli
p
student
ttest
lower
control
mice
fig
supplementari
figur
histopatholog
examin
reveal
treatment
amelior
virusassoci
pulmonari
inflammatori
infiltr
bronchopneumonia
fig
taken
togeth
result
demonstr
vivo
protect
effect
lethal
infect
extraordinari
potenc
broad
antivir
spectrum
hint
cellular
target
vulner
upstream
effector
use
tool
compound
tri
deciph
key
compon
lipid
metabol
exhibit
broad
relev
human
viral
infect
first
use
immunofluoresc
test
visual
distribut
pattern
cellular
lipid
droplet
ld
cholesterol
presenc
absenc
merscovinfect
cell
liver
cell
highli
activ
lipid
metabol
infect
merscov
markedli
enhanc
accumul
ld
cholesterol
wherea
addit
significantli
reduc
accumul
fig
valid
observ
mrna
express
lipogen
gene
lipid
biosynthesi
pathway
investig
signific
decreas
mrna
express
detect
gene
involv
fatti
acid
biosynthesi
upper
panel
fig
gene
cholesterol
synthesi
pathway
lower
panel
fig
infect
cell
compar
dmsotreat
infect
control
moreov
profound
increas
major
lipogen
enzym
includ
acetylcoa
carboxylas
acc
fatti
acid
synthas
fa
hmgcoa
synthas
hmgc
associ
merscov
infect
indic
viru
rapidli
upregul
lipid
biosynthesi
might
antagon
chang
therebi
reduc
viru
replic
search
upstream
protein
regul
host
lipogen
pathway
show
srebp
major
factor
control
lipid
biosynthesi
transactiv
gene
encod
lipogen
evalu
role
srebp
merscov
replic
compar
growth
merscov
wildtyp
control
cell
mock
srebp
gene
silenc
hyperexpress
cell
notabl
transfect
sirna
diminish
precursor
srebp
presrebp
product
significantli
p
oneway
anova
reduc
merscov
replic
fig
though
express
level
doubl
knockdown
reduc
individu
knockdown
amount
sirna
srebp
appli
doubl
knockdown
srebp
result
p
oneway
anova
decreas
infecti
viru
particl
compar
reduct
individu
knockdown
indic
potenti
synergist
effect
activ
inhibit
togeth
result
indic
srebp
essenti
merscov
replic
transactiv
lipid
biosynthesi
gene
requir
cleavag
presrebp
releas
ntermin
nuclear
form
nsrebp
process
regul
overexpress
either
howev
diminish
antivir
potenc
upon
merscov
infect
fig
togeth
result
indic
provir
role
nsrebp
merscov
replic
inhibitori
role
nsrebp
activ
confirm
function
andor
affect
report
gene
assay
reflect
srebpsdepend
transcript
activ
perform
shown
fig
lipogen
enzym
hmgc
fa
block
transcript
level
howev
liver
x
receptor
respons
element
lxre
requir
activ
affect
result
indic
might
specif
disrupt
transactiv
lipogen
enzym
mediat
nsrebp
fa
hmgc
two
lipogen
enzym
belong
separ
lipid
biosynthesi
pathway
inhibit
gene
transactiv
shown
fig
led
us
suspect
function
interrupt
interact
nsrebp
sre
conserv
lipogen
promot
includ
fa
acc
hmgc
etc
end
transcript
factor
assay
perform
specif
doubl
strand
dna
dsdna
sequenc
contain
sre
immobil
solid
phase
bind
intens
nuclearextract
detect
presenc
absenc
inhibitor
notabl
inhibit
bind
fig
supplementari
figur
correspond
sre
wherea
compound
ficz
supplementari
figur
determin
whether
target
nsrebp
sre
preincub
either
immobil
sredsdna
ad
nsrebp
nsrebp
bind
sredsdna
take
exampl
found
bind
sredsdna
inhibit
sredsdna
bind
activ
dosedepend
fashion
fig
next
determin
interact
residu
nsrebp
respons
bind
first
perform
molecular
dock
analysi
use
publish
crystal
structur
ref
vshape
dnabind
domain
show
structur
similar
bind
homodim
fig
take
exampl
bind
ebox
site
four
amino
acid
highli
conserv
among
protein
supplementari
figur
major
interact
predict
residu
hydrogen
bond
importantli
determin
sre
complet
conserv
human
mous
srebp
lower
panel
fig
may
explain
conserv
broad
spectrum
antivir
properti
human
cell
mous
model
explor
inhibit
dnabind
activ
srebp
physic
block
sre
recognit
ie
via
introduc
mutat
compar
bind
capac
wildtyp
protein
probe
biotin
photoaffin
tag
synthes
facilit
evalu
bind
characterist
made
introduc
linker
arm
contain
azido
end
carboxyl
acid
group
yield
design
addit
trifunct
linker
uv
photoaffin
biotin
tag
specif
probe
function
fig
like
inhibit
merscov
replic
vero
cell
supplementari
figur
next
use
azidoreact
green
fluoresc
dye
local
found
larg
host
cell
nucleu
corrobor
hypothesi
may
target
lipogen
transactiv
event
fig
captur
bind
target
immobil
streptavidinconjug
agaros
biotin
group
incub
transfect
cell
lysat
express
wt
known
receptor
cotransfect
control
ultraviolet
irradi
activ
crosslink
photoaffin
tag
complex
fix
isol
shown
fig
almost
equal
amount
precipit
wt
mutant
group
indic
biolog
function
howev
significantli
wt
detect
suggest
stronger
bind
affin
wt
addit
sre
bind
activ
significantli
p
student
ttest
diminish
substitut
arginin
highlight
crucial
role
sre
recognit
supplementari
figur
taken
togeth
conclud
disrupt
sre
bind
specif
via
impair
srerecognit
function
disrupt
nsrebp
sre
interact
lead
failur
lipogen
transactiv
elucid
downstream
consequ
investig
one
srebpmedi
pathway
fatti
acid
synthesi
first
explor
abil
endproduct
de
novo
fatti
acid
biosynthesi
pathway
sodium
palmit
revers
antivir
activ
notabl
fa
inhibitor
specif
fatti
acid
biosynthesi
pathway
show
antimerscov
activ
fig
addit
sodium
palmit
affect
viru
yield
merscovinfect
cell
treat
dmso
increas
viru
yield
p
oneway
anova
merscovinfect
cell
treat
either
fig
find
suggest
merscov
replic
hijack
host
fatti
acid
synthesi
inhibit
shutdown
lipogen
transactiv
rescu
exogen
palmit
next
explor
whether
fatti
acid
synthesi
critic
involv
replic
virus
end
replic
rescu
assay
use
negativestrand
rna
viru
repres
nonenvelop
rna
viru
repres
dna
viru
repres
perform
fig
inde
signific
p
student
ttest
extent
rescu
achiev
virus
especi
viru
p
student
ttest
addit
sodium
palmit
positivesens
rna
virus
known
replic
genom
intracellular
membran
merscov
doublemembran
vesicl
dmv
provid
anchor
scaffold
viral
replicationtranscript
complex
might
disrupt
blockad
fatti
acid
synthesi
use
electron
microscopi
perinuclear
dmv
cluster
readili
detect
merscovinfect
cell
left
panel
fig
contrast
almost
dmv
visual
treatment
right
panel
fig
sinc
coexpress
merscov
suffici
induc
dmv
use
treat
cell
cotransfect
kda
kda
h
shown
fig
signific
chang
detect
express
level
viral
protein
find
indic
reduc
dmv
format
caus
inhibit
lipogenesi
directli
decreas
viral
replic
indirectli
negativesens
rna
virus
influenza
virus
util
differ
mechan
genom
replic
transcript
independ
intracellular
replic
organel
palmitoyl
downstream
consequ
fatti
acid
synthesi
posttransl
modif
modul
protein
function
protein
local
context
influenza
virus
best
character
palmitoyl
protein
surfac
glycoprotein
hemagglutinin
ha
therefor
explor
whether
blockad
fatti
acid
synthesi
would
imped
influenza
ha
palmitoyl
inhibit
replic
haoverexpress
cell
cultur
vehicl
dmso
posit
control
inhibitor
specif
protein
palmitoyl
ha
protein
purifi
via
resinassist
captur
strikingli
reduc
level
palmitoyl
ha
observ
addit
compar
dmso
control
fig
moreov
also
show
inhibit
merscov
replic
dosedepend
manner
supplementari
figur
examin
specif
oleic
acid
downstream
metabolit
palmit
also
use
complement
assay
result
show
addit
oleic
acid
could
rescu
influenza
viru
replic
inde
complement
viral
growth
merscov
zikv
fig
c
find
suggest
palmitoyl
viral
ha
main
target
influenza
viru
inhibit
overal
use
dmv
format
viral
protein
palmitoyl
two
import
downstream
consequ
srebpsdepend
pathway
demonstr
suppress
srebpsdepend
lipogen
transactiv
reduc
viral
propag
fit
interven
downstream
fatti
acid
biosynthet
pathway
virus
reli
metabol
network
cellular
host
provid
energi
build
block
replic
previou
studi
viral
perturb
host
lipid
metabol
abl
identifi
underli
mechan
host
factor
target
invad
viru
remark
vitro
vivo
antivir
efficaci
tool
compound
inhibit
srebprel
pathway
confirm
upregul
host
lipid
biosynthesi
crucial
multipl
aspect
viral
life
cycl
suggest
aspect
vulner
antivir
intervent
srebpsmedi
lipogenesi
affect
build
membran
block
energi
suppli
posttransl
protein
modif
complex
process
cross
talk
compensatori
mechan
influenc
propag
divers
group
virus
fig
despit
complex
dnabind
activ
nsrebp
potenti
import
target
therapeut
intervent
broad
spectrum
pathogen
virus
tang
et
previous
report
betulin
inhibit
matur
srebp
induc
interact
srebp
cleavag
activ
protein
scap
insulininduc
gene
protein
insig
inde
betulin
presrebp
cleavag
inhibitor
pf
exhibit
inhibitori
effect
merscov
replic
nontox
concentr
supplementari
figur
cholesterol
metabolit
inhibit
infect
broad
rang
pathogen
virus
work
indirectli
sensor
protein
elicit
scapinsig
act
differ
inhibitor
studi
support
proteolyt
process
srebp
may
also
feasibl
target
broadspectrum
antivir
therapi
similar
studi
use
cancer
cell
line
usual
underw
complex
genet
metabol
rearrang
may
affect
interpret
addit
usag
odd
carbon
chain
glycerophospholipid
intern
standard
pc
pe
pg
addit
standard
directli
biolog
sampl
lipid
extract
would
equit
use
futur
lipidom
sampl
import
srebp
regulatori
pathway
implic
life
cycl
hantaviru
depend
lipid
synthesi
viru
entri
membran
fusion
also
exemplifi
pharmacolog
inhibit
fa
cerulenin
impair
replic
broadspectrum
virus
specif
hcmv
influenza
viru
infect
may
requir
fatti
acid
synthesi
modul
membran
composit
viral
bud
protein
direct
inhibit
fa
reduc
infect
respiratori
syncyti
viru
human
rhinoviru
serotyp
chang
membran
compon
virion
progeni
particl
denv
recruit
fa
site
replic
stimul
fatti
acid
distinct
studi
work
underscor
indispens
srebpmedi
fatti
acid
synthesi
multipl
postvirusentri
event
particularli
emerg
infecti
virus
merscov
influenza
viru
exampl
reduc
dmv
format
viral
protein
palmitoyl
two
import
consequ
srebpcontrol
fatti
acid
synthesi
inhibit
fig
g
studi
viral
replic
process
relat
srebpmedi
downstream
pathway
warrant
furthermor
demonstr
inhibit
divers
virus
includ
envelop
merscov
nonenvelop
rna
dna
virus
could
partial
rescu
exogen
suppli
palmit
differ
extent
fig
result
also
support
requir
de
novo
fatti
acid
synthesi
optim
viral
replic
moreov
transcript
inactiv
lipogen
enzym
addit
fa
may
impair
viru
replic
divers
pathway
virusspecif
manner
fig
unexpect
result
studi
antivir
activ
neither
depend
pathway
supplementari
figur
activ
host
innat
immun
respons
supplementari
figur
e
possibl
offtarget
effect
lead
broad
antivir
activ
exclud
compound
long
known
agonist
moreov
smallmolecul
compound
multitarget
binder
due
intrins
structur
featur
elicit
biolog
respons
one
ligandtarget
interact
found
present
may
necessarili
account
observ
antivir
activ
although
teratogen
effect
prodifferenti
agonist
cytotox
report
mous
anticip
therapeut
benefit
outweigh
side
effect
consid
short
durat
treatment
anim
experi
explor
analog
compar
potenc
improv
bioavail
oral
activ
retinoid
treatment
acut
promyelocyt
leukemia
identifi
supplementari
tabl
tamibaroten
known
safeti
profil
market
japan
clinic
experi
tamibaroten
believ
compound
could
modifi
safe
broad
group
antivir
therapeut
compound
overal
target
srebpassoci
lipid
biosynthet
pathway
demonstr
lipidom
reprogram
host
cell
variou
virus
expos
vulner
target
therapeut
intervent
human
embryon
kidney
atcc
cell
human
lung
carcinoma
atcc
cell
human
hepatoma
jcrb
cell
human
rhabdomyosarcoma
rd
atcc
cell
human
epitheli
type
atcc
cell
human
lung
adenocarcinoma
atcc
cell
human
leukem
atcc
monocyt
madindarbi
canin
kidney
mdck
atcc
cell
african
green
monkey
kidney
vero
atcc
cell
atcc
cell
maintain
dulbecco
modifi
eagl
medium
dmem
cultur
medium
supplement
heatinactiv
fetal
bovin
serum
fb
uml
penicillin
cell
line
confirm
free
mycoplasma
contamin
plasmo
test
invivogen
monocyt
prepar
differenti
perform
accord
establish
hsaec
atcc
cultur
airway
epitheli
cell
basal
medium
accord
manufactur
protocol
upon
viru
infect
infect
cell
maintain
fbsfree
medium
without
compound
merscov
gift
dr
ron
fouchier
sarscov
propag
cell
influenza
viru
strain
ahong
cultur
embryon
chicken
egg
enteroviru
cultur
rd
cell
clinic
isol
zikv
puerto
rico
strain
gift
dr
brandi
russel
dr
barbara
johnson
center
diseas
control
prevent
usa
amplifi
vero
cell
clinic
isol
human
adenoviru
type
propag
cell
cultur
virus
titrat
pfu
assay
andor
tissu
cultur
infecti
dose
assay
andor
rtqpcr
viru
stock
kept
aliquot
rtqpcr
assay
also
appli
quantif
gene
copi
interest
use
roch
lightcycl
realtim
pcr
system
primer
sequenc
provid
supplementari
tabl
fasluc
contain
fa
promot
gift
dr
bruce
spiegelman
addgen
plasmid
psynsretluc
name
hmgcsluc
clariti
contain
hmgc
promot
addgen
plasmid
addgen
plasmid
addgen
plasmid
gift
dr
timothi
osborn
luciferas
construct
isreluc
provid
dr
dongyan
jin
univers
hong
kong
lxre
report
plasmid
name
lxreluc
studi
obtain
system
bioscienc
purchas
cayman
chemic
michigan
unit
state
remdesivir
custom
synthes
wuxi
apptec
tianjian
china
chemic
inhibitor
obtain
sigmaaldrich
st
loui
missouri
unit
state
unless
specifi
fluoresc
neutral
lipid
dye
bodipi
invitrogen
use
stain
ld
filipin
iii
cayman
chemic
employ
visual
intracellular
cholesterol
phosphineactiv
fluoresc
dye
invitrogen
util
specif
label
detect
azidotag
molecul
ie
dapi
sigma
sigma
use
nuclear
cell
membran
stain
respect
merscov
np
detect
guinea
pig
antimerscov
np
serum
primari
antibodi
human
abcam
santa
cruz
proteintech
actin
abcam
antiinfluenza
ha
antibodi
genetex
flag
tag
sigma
use
relev
experi
uncrop
western
blot
provid
supplementari
figur
alexa
fluor
goat
antiguinea
pig
igg
h
l
antibodi
invitrogen
util
secondari
antibodi
immunofluoresc
stain
silenc
select
human
sirna
silenc
select
human
sirna
silenc
select
sirna
neg
control
obtain
life
technolog
nuclear
extract
perform
use
commerci
kit
abcam
accord
manufactur
protocol
transcript
factor
assay
kit
transcript
factor
assay
kit
abcam
use
determin
sre
bind
activ
respect
badrilla
leed
uk
kit
use
purif
palmitoyl
protein
cell
mock
infect
infect
merscov
moi
incub
dmem
medium
hpi
total
cellular
rna
virusinfect
noninfect
group
n
collect
gene
express
follow
merscov
infect
analyz
use
rnaseq
sequenc
librari
construct
sequenc
beij
genom
institut
bgi
averag
gener
clean
read
filter
low
qualiti
clean
read
map
refer
sequenc
use
ref
deg
merscovinfect
sampl
submit
david
server
pathway
enrich
cluster
analysi
gene
ontolog
go
enrich
analysi
deg
implement
use
goseq
r
koba
softwar
use
examin
statist
enrich
deg
kyoto
encyclopedia
gene
genom
kegg
cell
mock
infect
infect
merscov
moi
incub
dmem
medium
hpi
cell
collect
cellular
lipid
extract
inactiv
viru
infect
confirm
process
use
liquid
chromatographymass
spectrometri
lcm
grade
water
methanol
acetonitril
purchas
jt
baker
center
valley
pa
usa
hplcgrade
chloroform
purchas
merck
darmstadt
germani
analyt
grade
acet
acid
commerci
standard
use
biomark
identif
purchas
sigmaaldrich
mo
usa
intern
standard
includ
arachidon
lysoplateletactiv
factor
paf
purchas
cayman
cayman
chemic
usa
sampl
prepar
perform
minor
modif
accord
mplex
medium
remov
infect
cell
hpi
cell
immedi
wash
twice
icecool
quench
buffer
consist
methanol
ammonium
bicarbon
water
remov
quench
buffer
icecold
mm
ammonium
bicarbon
solut
ad
dissoci
cell
cell
scrape
transfer
ml
tube
nunc
thermo
fisher
usa
ice
fifti
microlit
cell
suspens
remov
dna
extract
perform
cell
count
normal
genom
dna
minikit
qiagen
germani
use
dna
extract
ml
lipid
extract
solut
chloroformmethanol
vv
contain
ad
tube
aliquot
mix
solut
remov
confirm
steril
infect
assay
lipid
extract
remain
solut
centrifug
rpm
min
bottom
phase
transfer
glass
vial
vial
remov
bsc
bsl
contain
laboratori
appropri
disinfect
dri
vacuum
concentr
dri
sampl
reconstitut
solvent
mixtur
contain
chloroformmethanol
vv
centrifug
rpm
min
supernat
transfer
lc
vial
lcm
analysi
cell
lipid
extract
analyz
use
acquiti
uplc
system
coupl
synapt
mass
spectromet
system
water
corp
usa
chromatographi
perform
water
acquiti
beh
column
mm
id
mm
water
milford
usa
mobil
phase
consist
acet
acid
water
b
acetonitril
separ
perform
flow
rate
mlmin
gradient
program
follow
b
min
b
min
b
min
b
min
b
min
b
min
order
achiev
rapid
equival
flow
rate
chang
mlmin
min
subsequ
gradient
program
appli
follow
b
min
b
min
b
min
column
autosampl
temperatur
maintain
respect
inject
volum
mass
spectral
data
acquir
posit
neg
mode
capillari
voltag
sampl
cone
voltag
sourc
offset
maintain
kv
v
v
respect
nitrogen
use
desolv
ga
flow
rate
lh
sourc
desolv
temperatur
maintain
respect
mass
spectra
acquir
mz
rang
synapt
hdm
system
calibr
use
sodium
format
cluster
oper
sensit
mode
leucin
enkephalin
use
lock
mass
experi
ms
data
acquir
mode
mse
lipid
profil
msm
acquisit
oper
paramet
ms
acquisit
lipid
identif
collis
energi
use
rang
ev
fragment
allow
put
identif
structur
elucid
signific
lipid
acquisit
raw
data
perform
use
masslynx
softwar
version
water
corp
usa
raw
data
firstli
convert
analysi
base
file
abf
format
convert
data
subsequ
deconvolv
mass
featur
mf
list
use
msdial
softwar
http
primepscrikenjp
version
process
data
export
text
file
statist
analysi
total
ion
intens
mf
msdial
report
file
sampl
normal
correspond
dna
concentr
calibr
cell
count
metaboanalyst
http
wwwmetaboanalystca
use
univari
multivari
statist
analysi
normal
mf
subject
pareto
scale
univari
analysi
statist
signific
featur
determin
among
mock
merscov
infect
group
use
student
ttest
respect
pvalu
consid
statist
signific
featur
multivari
analysi
orthogon
partial
leastsquar
discrimin
analysi
oplsda
perform
supervis
method
find
import
variabl
discrimin
power
model
evalu
relev
protocol
lipid
identif
carri
accord
publish
statist
signific
featur
given
annot
name
msdial
ms
featur
could
match
intern
librari
criterion
mf
signific
abund
select
msm
experi
analysi
put
lipid
identifi
use
exact
molecular
weight
nitrogen
rule
fragment
literaturedatabas
search
includ
metlin
databas
http
metlinscrippsedu
human
metabolom
databas
http
wwwhmdbca
lipidmap
http
wwwlipidmapsorg
kegg
databas
http
wwwgenomejpkegg
final
confirm
lipid
ident
use
authent
chemic
standard
msm
fragment
pattern
chemic
standard
compar
candid
lipid
lcm
condit
joint
lipidom
transcriptom
analysi
done
metaboanalyst
version
enabl
simultan
map
upregul
gene
chang
lipid
merscov
infect
librari
compound
cayman
chemic
michigan
usa
includ
prostaglandin
receptor
agonist
antagonist
ceramid
deriv
ideal
g
proteincoupl
receptor
screen
use
pharmacolog
screen
mttbase
cpe
inhibit
assay
perform
identifi
compound
could
protect
cell
viru
identifi
antimerscov
inhibitor
confluent
cell
cultur
plate
cellswel
triplic
infect
merscov
moi
one
hour
viru
absorpt
inoculum
remov
follow
addit
drugcontain
medium
twentyfour
hour
later
mgml
mtt
solut
sigma
ad
well
monolay
incub
h
final
sd
hcl
ad
sampl
incub
presenc
overnight
color
chang
read
refer
wavelength
screen
inhibitor
mdck
cell
infect
moi
cell
viabil
score
hpi
procedur
antimerscov
screen
remdesivir
favipiravir
use
posit
control
merscov
respect
next
analysi
use
perform
evalu
vitro
antivir
efficaci
primari
hit
individu
compound
serial
dilut
test
either
antimerscov
activ
select
index
si
compound
calcul
ratio
cellular
cytotox
concentr
inhibitori
concentr
valu
determin
mtt
assay
celltiterglo
assay
promega
accord
manufactur
protocol
data
obtain
pra
viral
load
reduct
assay
calcul
use
graphpad
prism
intracellular
stain
cell
detach
mm
edta
pb
fix
paraformaldehyd
permeabil
triton
pb
immunostain
flow
cytometri
perform
follow
standard
flow
cytometri
perform
use
bd
facscanto
ii
flow
cytomet
bd
bioscienc
data
analyz
use
flowjo
vx
tree
star
gate
strategi
provid
supplementari
figur
intestin
organoid
intestinoid
cultur
differenti
merscov
infect
ex
vivo
cultur
inoculum
pfu
merscov
use
infect
one
droplet
intestinoid
estim
moi
inoculum
remov
virusinocul
intestinoid
rins
pb
reembed
matrigel
cultur
plate
cultur
medium
contain
lack
indic
time
point
intestinoid
harvest
quantif
intracellular
viral
load
wherea
cellfre
matrigel
cultur
medium
combin
viral
titrat
extracellular
virion
use
standard
plaqu
assay
merscov
viru
test
tg
balbc
respect
examin
antimerscov
activ
total
mice
evalu
anesthesia
mice
intranas
inocul
viru
suspens
contain
pfu
merscov
intraperiton
ip
therapeut
treatment
initi
h
postviruschalleng
one
group
mice
inocul
ip
day
mgkgday
untreat
control
group
mice
administ
dmso
pb
ip
anim
surviv
clinic
diseas
monitor
day
death
four
mice
group
euthan
randomli
day
postchalleng
respect
mous
lung
brain
collect
viru
titrat
h
e
histopatholog
evalu
antiinfluenza
viru
potenc
vivo
balbc
mice
micegroup
inocul
pfu
viru
treatment
initi
h
postviru
challeng
administr
one
group
mice
inocul
mgkgday
second
group
treat
zanamivir
mgkgday
posit
control
third
group
given
dmso
pb
untreat
control
two
dose
per
day
zanamivir
dmso
administ
day
total
dosesmous
anim
surviv
clinic
diseas
monitor
day
death
lung
tissu
micegroup
collect
viral
load
detect
h
e
histopatholog
analys
day
postviruschalleng
respect
crystal
structur
pdb
code
pdb
code
retriev
protein
data
bank
databas
dimer
dimer
separ
pymol
miss
residu
model
use
itass
protein
model
prepar
protein
prepar
wizard
modul
conform
download
pubchem
leadfind
v
use
perform
dock
simul
extra
precis
align
amino
acid
sequenc
perform
use
vector
nti
thermo
fisher
scientif
use
intracellular
visual
design
synthes
pulldown
bind
target
synthes
mg
mix
ml
mgml
dissolv
dimethylformamid
dmf
next
mg
bi
dimethylamino
methylen
pyridinium
hexafluorophosph
n
ndiisopropylethylamin
dipea
ml
dichloromethan
ad
final
volum
ml
reaction
perform
room
temperatur
shake
overnight
incub
reaction
mixtur
lyophil
remov
solvent
purifi
hplc
mz
detect
mass
spectrometri
ms
final
yield
quantifi
nuclear
magnet
reson
nmr
synthes
purifi
link
amin
reactiv
trifunct
crosslink
lysinylamido
n
sulfosuccinimidylcarboxi
ethyl
disulfid
sodium
salt
santa
cruz
biotinuv
activatingnhydroxysuccinimid
nh
ester
compound
trifunct
crosslink
contain
nhsester
head
group
link
amin
tail
anoth
crosslink
phosphin
compound
methyl
ethoxi
ethylcarbamoyl
shinsei
chemic
compani
ltd
biotin
head
group
streptavidin
bind
end
uv
activ
benzophenon
group
crosslink
target
bind
protein
specif
mg
trifunct
linker
compound
mix
mm
crosslink
phosphin
compound
dissolv
final
volum
ml
dmf
molar
ratio
compound
reaction
perform
shake
rpm
excess
ad
mixtur
allow
crosslink
phosphin
group
stauding
ligat
reaction
reaction
product
incub
streptavidin
agaros
resin
pierc
captur
product
electron
microscopi
util
observ
dmv
induc
merscov
infect
vero
cell
grown
sixwel
plate
follow
infect
merscov
moi
h
cell
cultur
medium
replac
fresh
medium
contain
dmso
control
h
cell
cultur
medium
remov
cell
wash
pb
trypsin
fix
glutaraldehyd
process
imag
acquir
philip
transmiss
electron
microscop
locat
electron
microscop
unit
univers
hong
kong
indic
figur
legend
experi
perform
independ
least
three
time
experi
use
sampl
collect
mice
whole
experiment
set
use
differ
treatment
harvest
singl
anim
statist
analys
conduct
use
graphpad
prism
version
error
bar
indic
standard
deviat
pvalu
calcul
use
either
student
ttest
oneway
anova
logrank
test
indic
p
p
p
major
usag
experiment
model
subject
involv
studi
evalu
broadspectrum
antivir
effect
multipl
cell
line
mous
model
human
primari
cell
organoid
system
protocol
approv
institut
review
board
univers
hong
konghospit
author
hong
kong
west
cluster
normal
small
intestin
tissu
patient
obtain
surgic
human
peripher
blood
macrophag
mdm
isol
healthi
blood
donor
hong
kong
red
cross
blood
transfus
servic
inform
consent
obtain
human
particip
experi
perform
complianc
approv
standard
oper
procedur
human
dipeptidyl
peptidas
transgen
mice
male
femal
balbc
femal
mice
kept
biosafeti
level
hous
given
access
standard
pellet
feed
water
ad
libitum
experiment
protocol
approv
anim
ethic
committe
univers
hong
kong
perform
accord
standard
oper
procedur
biosafeti
level
anim
facil
experi
live
virus
conduct
use
biosafeti
level
culatr
follow
hong
kong
legisl
associ
assess
accredit
laboratori
anim
care
intern
recommend
standardsguidelin
http
wwwaaalacorgabout
guidelin
cfm
inform
experiment
design
avail
natur
research
report
summari
link
articl
